A population-based study to estimate survival and standardized mortality of tuberous sclerosis complex (TSC) in Taiwan

Jui-Hui Peng1,2*, Hung-Pin Tu3 and Chien-Hui Hong1,4*

Abstract

Background: Tuberous sclerosis complex (TSC) is an autosomal dominant disease with systemic manifestations, which can cause significant mortality and morbidity. Population-based epidemiological studies on TSC mortality and survival remain scarce, though several recent studies provide evidence that TSC survival rates are high and disease prognosis is fair for most patients. This study aims to estimate the life expectancy and mortality statistics in Taiwanese TSC patients, investigate prognosis and associations of TSC mortality based on demographic variables, and compare these results to past literature, especially for Asian patients.

Methods: Taiwanese National Health Insurance (NHI) insurees can obtain Catastrophic Illness Certificates (CIC) for certain eligible diseases to waive copayments after diagnosis by two independent physicians. CIC holders for TSC during 1997–2010 were identified from the NHI Research Database. Queries on enrollment (CIC acquisition) age, endpoint (end of query period or death) age, sex, and comorbidities were obtained. Patients were separated into cohorts (endpoint age, sex, and age of diagnosis), and analyzed accordingly.

Results: 471 patients (232 male, 239 female) were identified, of which 14 died. Compared to literature, patients showed similar demographics (age range, diagnosis age, sex distribution); similar manifestations and prevalence (epilepsy, intellectual disability, renal disease); lower disease prevalence (1 in 63,290); lower mortality (0.21% per year); and near-identical standardized mortality ratio (4.99). A cumulative mortality of 4.08% was found over 14 years, though mortality plateaued at 7 years post-enrollment, suggesting a good overall survival rate; comparable with previous studies in Asian patients. Enrollment age was a significant prognostic factor, with late-enrollment (age > 18) patients at higher risk for all-cause mortality (Hazard ratio = 6.54). Average remaining lifetime was significantly lower than the general population, and decreased with age.

Conclusions: This study reports a population-based disease database, highlights the importance of diagnosis age in prognosis prediction, and suggests the role of renal manifestations in mortality. Furthermore, it corroborates recent TSC studies in the Asian population in terms of survival. Overall, physician vigilance, early diagnosis, and careful monitoring are beneficial for disease outcome and patient survival.

Keywords: Tuberous sclerosis complex, Epidemiology, Mortality, Cohort study, National Health Insurance Database

Background

Tuberous sclerosis complex (TSC) is a rare, autosomal dominant disease of variable penetrance, which results from mutations in the genes TSC1 (which codes for hamartin) or TSC2 (which codes for tuberin), respectively. The hamartin-tuberin complex plays diverse roles...
in cell cycle regulation, chiefly through inhibition of the mammalian target of rapamycin (mTOR) cascade [1–3]. Clinical hallmarks of TSC include characteristic dermatologic lesions (shagreen patches, hypopigmented macules); systemic benign neoplasms (hamartomas, such as facial angiofibromas) [4]; and hamartoma-associated manifestations, such as epilepsy, renal angiomyolipoma (AML), pulmonary lymphangioleiomyomatosis (LAM), and neuropsychiatric symptoms known as TSC-associated neuropsychiatric disorders (TAND) [1–4]. The severity of TSC varies substantially, with TSC2 mutations associated with more severe phenotypes, including learning disabilities and epilepsy, which are in turn associated with TAND [5]. A single-center British study [6] (n=284) found significantly higher mortality in patients with learning disabilities (9% vs. 2%), indicating the possible effects of genotype on survival rates. The location of mutation, severity of protein disruption, and somatic mutation of the wild-type copy may also play a role [7].

First described in 1880 [8], TSC remained relatively unknown until groundbreaking advances in the last two decades provided much better understandings of its pathophysiology. We previously reported TSC prevalence and incidence at 1/95,136 [9] and 0.153 per 100,000 person-years (PY) [10], respectively. However, accurate estimates of incidence, mortality rates (MR), and survival remain rare: many large studies have relied on clinical-based datasets from specialist centers (‘TSC Centers’), which may limit the applicability and generalizability of results. A recent study in Hong Kong, following up 321 patients (37 who died) from 1995–2018, showed that the survival rate of TSC patients at 20 years old and 50 years old were 98.6 and 79.5%, respectively [11]. Whether this mortality rate could be extrapolated to that in other Asian countries warrants further independent studies.

While TSC diagnosis is often made early in life based on cutaneous and epileptic manifestations, and sometimes prenatally through fetal echocardiography of cardiac rhabdomyomas [12], many symptoms exhibit themselves much later, putting undiagnosed patients at significant risk of morbidity and mortality [13, 14]. Furthermore, although TSC patients are known to experience higher mortality than the general population, there are few reports on the death rate, standardized mortality ratio (SMR), and estimated life expectancy; difficulties include clinical-based methodology, censored data, limited observation time, small sample size, and unclear mortality causes. As criteria, technology, and physician awareness changed, diagnostic rates have improved, necessitating more recent, population-based data for epidemiological considerations. To this end, we aim to estimate the life expectancy and mortality statistics in Taiwanese TSC patients, describe Taiwanese patient demographics in terms of age, sex, diagnosis age, and comorbidities, and investigate patient prognosis and associations of TSC mortality based on those variables.

Methods

Taiwan’s National Health Insurance (NHI), a government-administrated, single-payer universal healthcare program, has consistently achieved excellent coverage since its inception in 1995. 95% of the Taiwanese population of >21 million people were covered in 1997, which grew to >99.5% of >23 million in 2010 [15, 16]; making the NHI Research Database (NHIRD) one of the world’s largest and most comprehensive national healthcare databases. NHI insurers may apply for a Catastrophic Illness Certificate (CIC) if diagnosed with an eligible disease (for TSC, ‘Probable’ or ‘Definite’ disease according to the 1992 [17] or 1998 [18] criteria, with confirmation by two independent physicians). Since CICs allow waiver of all copayments incurred by the specified disease, those eligible have a strong incentive to apply as soon as possible, making the CIC database an accurate and lossless representation of all diagnosed TSC patients in Taiwan.

An NHIRD dataset of TSC CIC holders in a 14-year period (1997–2010, inclusive) was obtained. To safeguard patient confidentiality, the dataset was scrambled twice by the NHIRD, with all identifying information purged before access. Queries for ages at ‘endpoint’ (defined as death or end of queried period), sex, dates of ‘enrollment’ (defined as CIC acquisition), dates of death, and comorbidities were made. In order to reduce possible coding or diagnostic bias, a ‘comorbidity’ was defined as an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnostic code recorded by attending physicians in over three outpatient claims for a single patient. Additional queries were made specifically for LAM (ICD-9-CM 516.4) owing to its lack of representation in the original query results.

Patients were separated into age blocs of <1, 1–18, 19–40, and >40 years (‘infant’, ‘child’, ‘adult’, and ‘older adult’, respectively) for both enrollment and endpoint ages. Two life tables with Average Remaining Lifetimes (ARL) were constructed for each age category using SAS abridged macro (version 9.4) [19, 20]. MRs were calculated through Kaplan–Meier functions, and 14-year SMR [21] was calculated using unadjusted national death rates. Mortality-associated variables were identified with Log-rank test based on Kaplan–Meier functions. Incidence rate ratios (IRR) for associations of mortality were calculated for sex and enrollment age; generalized linear models were used to perform Poisson regression analyses. Crude (bivariate) and adjusted (multivariate) hazard ratios (HR) were calculated using standard and stepwise Cox proportional hazards regression models,
Results

Patient demographics

During 1997–2010, 471 patients (49.3% male, 50.7% female) held CICs for TSC (Table 1); all obtained their CIC during the queried period. Mean and median age at endpoint was 20.9 and 17.8, respectively. Pediatric patients (age ≤ 18 at endpoint) made up 50.3% of the study population, compared to 4.7% of patients who were over 50 at endpoint. 75.5% of patients were enrolled before adulthood (mean age 15), with 31.6% enrolled before age 6 (Additional file 1: Fig. S1). There were no significant differences between sexes in most metrics investigated (Additional file 2: Table S1).

14 (3.0%) patients ranging from <1 to 61-years old (8 male, 6 female) died during the queried period, with 3 dying before adulthood (Additional file 3: Table S2). Compared to surviving patients, patients who died were on average older (age 32.4 vs. 20.4 at endpoint, P < 0.0001), enrolled later (enrolled at age 29.7 vs. 14.5, P < 0.0001), and died sooner after enrollment (2.6 vs. 5.9 years survived from enrollment to endpoint, P = 0.0003). Since all patients were enrolled within the query period, years survived from enrollment to endpoint is equal to follow-up time (mean 5.8 years, total 2749.11 person-years). Since diagnosed TSC patients have a strong incentive to obtain CICs as soon as possible, enrollment can be interpreted, to an extent, as analogous to ‘diagnosis.’ Table 2 outlines the comparison between enrollment age cohorts in various metrics.

Comorbidity

Comorbidities were sorted into neurological disorders, TAND, malignant neoplasms, benign tumours, and other systemic manifestations. Neurological disorders include epilepsy, multiple sclerosis, infantile cerebral palsy (ICP), and congenital nervous system anomalies (CNSA), among others. TAND include dementia, attention deficit hyperactivity disorder (ADHD), and developmental delays, among others. Malignant neoplasms include cancers in the oropharynx, heart, urological system, and brain, among others. Benign tumours include those in the skin, urological system, and brain. Other systemic manifestations include renal diseases, myocardial infarct, cerebrovascular diseases, peptic ulcers, diabetes mellitus (DM), and LAM. “Epilepsy” was the most common comorbidity (361; 76.6%), followed by “Any malignant neoplasm” (35.5%), “Developmental delays” (32.1%), and “CNSA” (30.1%). Epilepsy, ICP, CNSA, ADHD, developmental delays, and oropharyngeal cancers were associated with early-enrollment patients (≤18), while renal diseases, dementias, neurotic disorders, depression, DM, and benign and malignant urological tumours were associated with late-enrollment patients. Comorbidities showed no significant sex predominance (Table 2) aside from benign urological tumours (male 2.2%, female 7.1%). All codes are recorded in Table 1.

Life table, SMR

Life table according to endpoint age (Table 3a) calculated an ARL of 34.75 in childhood, while infants, adults, and older adults exhibited ARLs of 17.95, 19.35, and 7.60, respectively. Life table according to enrollment age (Table 3b) showed an ARL of ~31 for those enrolled before adulthood, and an ARL of 16.80 and 5.40 for those enrolled during adulthood and late adulthood, respectively. Since annual TSC mortality rates varied, SMR was calculated using cumulative instead of annual mortality. Expected deaths, derived from crude MR in the general Taiwanese population over the study period [16] without age- or sex-matching, was 0.0056–63 per year. Expected and observed death over 14 years was 2.81 and 14, respectively, translating to an SMR of 4.99 (P = 0.0028) (Table 3c).

Mortality: MR, IRR, and associated HR

Kaplan–Meier function showed a steady post-enrollment increase of cumulative mortality, until plateauing at 4.08% by year 7 (Fig. 1a). Late enrollment was found to be a major prognostic factor. Additional functions for enrollment age (Fig. 1b) found that early-enrollment patients exhibited lower cumulative mortality (1.82% vs. 9.94%), lower MR (1.96 vs. 14.05/1,000PY), and longer survival times (2,038.6 vs. 711.5PY). Adjusted mortality IRR for late enrollment was 6.60 (P = 0.0025), and crude HR was 6.54 (P = 0.0016). Sex was found to have no significant impact (Fig. 1c). Owing to scrambling protocols, causes of death were unavailable, limiting our analyses to association (Table 4). Only renal disease and benign urological tumours showed statistically significant association with mortality, though significance was lost after adjustments for endpoint age, sex, and other comorbidities. Subgroup analyses and P values for interaction (Additional file 4: Table S3) showed no significant inter-variable interaction between enrollment age and sex or comorbidities.
|                                               | Total   | Mortality group | Surviving group | P value |
|-----------------------------------------------|---------|-----------------|-----------------|---------|
|                                               | N       | N               | N               |         |
| **Table 1** Patients who held catastrophic illness certificates (CIC) for tuberous sclerosis complex (TSC) in Taiwan, 1997–2010 |         |                 |                 |         |
| **Sex, n (%)**                                |         |                 |                 |         |
| Male                                          | 232 (49.3) | 8 (57.1)        | 224 (49.0)      | 0.5970  |
| Female                                        | 239 (50.7) | 6 (42.9)        | 233 (51.0)      |         |
| **Age at endpoint (death or end of queried period), years** |         |                 |                 |         |
| Mean (SD)                                     | 20.9 (13.3) | 32.4 (17.3)     | 20.4 (13.0)     | <0.0001 |
| Median (IQR)                                  | 17.8 (11.5–27.2) | 32.8 (23.4–43.8) | 17.5 (11.3–26.4) | 0.0006  |
| **Cohorts by age at endpoint, n (%)**         |         |                 |                 |         |
| < 1 year                                      | 2 (0.4) | 1 (7.1)         | 1 (0.2)         |         |
| 1–18 years old                                | 235 (49.9) | 2 (14.3)        | 233 (51.0)      |         |
| 19–40 years old                               | 196 (41.6) | 6 (42.9)        | 190 (41.6)      |         |
| > 40 years old                                | 38 (8.1) | 5 (35.7)        | 33 (7.2)        | <0.0001 |
| **Age at enrollment (date of CIC acquisition), years** |         |                 |                 |         |
| Mean (SD)                                     | 15.0 (13.8) | 29.7 (17.8)     | 14.5 (13.4)     | <0.0001 |
| Median (IQR)                                  | 10.9 (4.1–21.9) | 31.6 (16.6–42.6) | 10.8 (4.0–21.3) | 0.0015  |
| **Cohorts by age at enrollment, n (%)**       |         |                 |                 |         |
| < 1 year                                      | 36 (7.6) | 1 (7.1)         | 35 (7.7)        |         |
| 1–18 years old                                | 279 (59.2) | 3 (21.4)        | 276 (60.4)      |         |
| 19–40 years old                               | 129 (27.4) | 5 (35.7)        | 124 (27.1)      |         |
| > 40 years old                                | 27 (5.7) | 5 (35.7)        | 22 (48)         | <0.0001 |
| ≤ 18 years old                                | 315 (66.9) | 4 (28.6)        | 311 (68.1)      |         |
| > 18 years old                                | 156 (33.1) | 10 (71.4)       | 146 (31.9)      |         |
| **Survived time from enrollment to endpoint, years** |         |                 |                 |         |
| Mean (SD)                                     | 5.8 (3.4) | 2.6 (2.1)       | 5.9 (3.4)       | 0.0003  |
| Median (IQR)                                  | 5.5 (3.1–8.1) | 2.2 (0.7–3.4)  | 5.6 (3.2–8.1)  | 0.0002  |
| Total                                         | 2749.11 | 2712.29         | 36.82           |         |
| **Comorbidity (ICD-9-CM diagnostic codes queried), n (%)** |         |                 |                 |         |
| **Neurological symptoms**                     |         |                 |                 |         |
| Epilepsy (345.x)                              | 361 (76.6) | 10 (71.4)       | 351 (76.8)      | 0.7479  |
| Cerebral degenerations (331.x)                | 8 (1.7) | 0 (0.0)         | 8 (1.8)         | 1.0000  |
| Multiple sclerosis (340.x)                    | 24 (5.1) | 1 (7.1)         | 23 (5.0)        | 0.5242  |
| Infantile cerebral palsy (343.x)              | 47 (10.0) | 2 (14.3)        | 45 (9.8)        | 0.6405  |
| Other congenital nervous system anomalies (742.x) | 142 (30.1) | 3 (21.4)       | 139 (30.4)      | 0.5679  |
| **TANDs**                                     |         |                 |                 |         |
| Dementias (290.x, 291.x, 294.x)               | 31 (6.6) | 1 (7.1)         | 30 (6.6)        | 1.0000  |
| Psychotic conditions (293.x–299.x)            | 73 (15.5) | 1 (7.1)         | 72 (15.8)       | 0.7062  |
| Neurotic disorders (300.x)                    | 22 (4.7) | 0 (0.0)         | 22 (4.8)        | 1.0000  |
| Depression (311.x)                            | 6 (1.3) | 0 (0.0)         | 6 (1.3)         | 1.0000  |
| ADHD (314.x)                                  | 31 (6.6) | 0 (0.0)         | 31 (6.8)        | 0.6136  |
| Developmental delays (315.x–319.x)            | 151 (32.1) | 1 (7.1)        | 150 (32.8)      | 0.9442  |
| Any malignant neoplasms (140.x–195.x)         | 167 (35.5) | 5 (35.7)       | 162 (35.4)      | 1.0000  |
| Oral and pharyngeal cancers (140.x–149.x)     | 34 (7.2) | 1 (7.1)         | 33 (7.2)        | 1.0000  |
| Cardiac cancer (164.1)                        | 5 (1.1) | 0 (0.0)         | 5 (1.1)         | 1.0000  |
| Urological cancers (189.x)                    | 11 (2.3) | 1 (7.1)         | 10 (2.2)        | 0.2851  |
| Brain cancer (191.x)                          | 18 (3.8) | 0 (0.0)         | 18 (3.9)        | 1.0000  |
| **Benign tumours**                            |         |                 |                 |         |
| Benign skin tumours (216.x)                   | 14 (3.0) | 0 (0.0)         | 14 (3.1)        | 1.0000  |
| Benign urological tumours (223.x)             | 22 (4.7) | 3 (21.4)        | 19 (4.2)        | 0.0231  |
Discussion

The 2010 prevalence for TSC in Taiwan was 1/63,290, higher than previously estimated (1/95,136) [9]. Prevalences reported by clinical-based studies in Japan (1/26,500 [24]; 1/29,990 [25]), Northern Ireland (1/25,000 [26]), Sweden (1/12,900 [27]), and Minnesota (1/14,490 [28]; 1/9,434 [29]) were surprisingly higher, with only one older study in Hong Kong reporting lower prevalence (> 1/170,000) [30], while a much more recent study from Hong Kong reported a prevalence closer to other values, at 1/25,833 [11]. National or registry-based studies in Germany (1/11,180–22,360 live births [31, 32]), Sweden (1/18,587 [33]), and Quebec (1/7,872 [34]) were also higher. Two trends are notable here: first, that prevalences in the same region varied significantly by time, seeing rapid increases in recent years (e.g. in Taiwan and Hong Kong), which is most likely due to advances in diagnostic rates; and second, that East Asian populations may experience comparatively lower rates of TSC, which may owe to underreporting, underdiagnosis, or unknown genetic mechanisms [35]. Nevertheless, adult prevalences remain consistently lower than neonatal values (1/6,000 live births) [1, 2], possibly due to TSC’s high childhood onset and mortality [25]. That being said, mildly symptomatic patients are likely to remain undiagnosed, making the true global prevalence impossible to ascertain. Additional file 5: Fig. S2 summarizes reported regional TSC prevalences in map form.

TOSCA (TuberOus Sclerosis registry to increase disease Awareness), which describes 2093 patients across 31 countries [36, 37], can be considered a suitable baseline for TSC patients. Compared to our results, TOSCA reported similar sex distribution (48.2% male, 51.8% female), but substantially younger diagnosis (mean 16.9, median 1.0) and enrollment (63.3% cases ≤ 18) ages. The difference is likely methodological: since over half of TOSCA data came from pediatric or neuropsychiatric facilities, adult TSC patients with few neurological symptoms may not have been well-represented. Other possibilities include insufficient physician awareness, changing criteria, or potentially milder TSC presentation in Taiwan. Interestingly, the recent population-based study from Hong Kong [11], whose populace is theoretically highly similar to that of Taiwan, reported a slight male predominance (1:0.81), a much higher percentage of adults (1:2.84), and a much higher overall prevalence (1/25,833). We think this may be due, at least in part, to the longer query period and later query date of the Hong Kong study (1995–2018), where advancements in diagnostic rates and therapeutic options for TSC patients in recent years may have allowed many mildly symptomatic individuals (who had been undiagnosed in childhood and therefore are now adults) to be diagnosed. Unfortunately, the dates and ages at diagnosis were not provided, so we were not able to verify this conjecture. Nonetheless, this apparent divergence is intriguing and merits further examination or comparison, as both regions share a common Han-Chinese predominating ethnic makeup and similar linguo-cultural traditions (which may affect variables such as willingness to seek medical aid, or utilization of traditional Chinese medicine).

The clinical profile of TSC mortality varies by literature, ranging from 4.8% to 13.8% in 10 to 34 years of follow-up [6, 11, 22, 33, 38–42]. Together, these studies describe 3657 patients (331 deaths) over an average of 21.2 years. Aggregate MR was 9.05%, with annual crude and weighted MR of 0.43% and 0.61%, respectively. In comparison, we observed significantly lower MR (0.21%/year; Table 3c), a larger age range, and a presence of pediatric deaths, though with similar sex distribution and median age. A Dutch study (n = 351) [40] reported an

| Total Mortality group | Surviving group |
|----------------------|---------------|
| N                    | N             | N              | P value |
| Benign brain tumours (225.x) | 13 (2.8) | 1 (7.1) | 12 (2.6) | 0.3280 |
| Any renal diseases (403.x, 404.x, 580.x-586.x) | 30 (6.4) | 3 (21.4) | 27 (5.9) | 0.0527 |
| Myocardial infarction (410.x, 411.x) | 1 (0.2) | 0 (0.0) | 1 (0.2) | 1.0000 |
| Cerebrovascular diseases (430.x-433.x, 435.x) | 2 (0.4) | 0 (0.0) | 2 (0.4) | 1.0000 |
| Peptic ulcers (531.x-534.x) | 10 (2.1) | 1 (7.1) | 9 (2.0) | 0.2627 |
| Diabetes mellitus (250.x) | 5 (1.1) | 0 (0.0) | 5 (1.1) | 1.0000 |
| LAM (516.4) | 3 (0.7) | 0 (0.0) | 3 (0.0) | 1.0000 |

For comparisons between the mortality and survival cohorts, P value was calculated using the T-test, Wilcoxon Rank Sum test, or chi-squared test/Fisher exact test, as appropriate. Abbreviations: SD: standard deviation; IQR: interquartile range; ICD-9-CM: International Classification of Diseases, Ninth Revision, Clinical Modifications; TAND: TSC-associated neuropsychiatric disorders; ADHD: attention deficit hyperactivity disorder.
Table 2  Associations of survival time, mortality rates (MR), incidence rate ratios (IRR), and comorbidities with diagnosis age or sex in tuberous sclerosis complex (TSC) patients

| Survival time after enrollment (mortality group) | Enrollment age ≤ 18 | Enrollment age > 18 | P value | Sex cohorts | Males | Females | P value |
|-----------------------------------------------|---------------------|---------------------|---------|-------------|-------|---------|---------|
| Mean (SD)                                      | 3.7 (2.8)           | 2.2 (1.9)           | 0.2743  | 1.6 (1.5)   | 4.0 (2.2) | 0.0356  |
| Median (IQR)                                   | 3.8 (1.8–5.5)       | 2.0 (0.7–3.0)       | 0.2579  | 1.3 (0.3–2.7)| 3.2 (2.0–6.7)| 0.0707  |
| Mortality rates and IRR                        |                     |                     |         |             |       |         |         |
| Death/total subjects                           | 4/315 (1.27)        | 10/156 (6.41)       | 0.2579  |             |       |         |         |
| Person-years survived for all subjects         | 2038.64             | 711.53              | 0.0356  |             |       |         |         |
| MR per 1000 person-years                       | 1.96                | 14.05               |         |             |       |         |         |
| 95% CI                                        | 1.88–2.05           | 13.06–15.13         |         |             |       |         |         |
| Crude IRR                                     | 1.00                | 7.16                | 0.0009  | 1.00        | 0.76  | 0.6136  |
| 95% CI                                        | 2.25–22.84          | 4.58–4.64           |         |             |       |         |         |
| Adjusted IRR                                  | 1.00                | 6.60                | 0.0025  | 1.00        | 0.72  | 0.5461  |
| 95% CI                                        | 1.95–22.4           | 2.62–2.19           |         |             |       |         |         |
| Comorbidities, n (% of cohort)                 |                     |                     |         |             |       |         |         |
| Neurological symptoms                          |                     |                     |         |             |       |         |         |
| Epilepsy                                      | 259 (82.2)          | 102 (65.4)          | <0.0001 | 182 (78.4)  | 179 (74.9)| 0.3848  |
| Cerebral degenerations                        | 4 (1.3)             | 4 (2.6)             | 0.4491  | 4 (1.7)     | 4 (1.7) | 1.00    |
| Multiple Sclerosis                            | 14 (4.4)            | 10 (6.4)            | 0.3781  | 13 (5.6)    | 11 (4.6)| 0.68    |
| Infantile cerebral palsy                      | 44 (14.0)           | 3 (1.9)             | <0.0001 | 23 (9.9)    | 24 (10.0)| 1.00    |
| Other congenital nervous system anomalies      | 110 (34.9)          | 32 (20.5)           | 0.0013  | 67 (28.9)   | 75 (31.4)| 0.62    |
| TANDs                                         |                     |                     |         |             |       |         |         |
| Dementias                                     | 10 (3.2)            | 21 (13.5)           | <0.0001 | 19 (8.2)    | 12 (5) | 0.1948  |
| Psychotic conditions                          | 42 (13.3)           | 31 (19.9)           | 0.065   | 42 (18.1)   | 31 (13.0)| 0.13    |
| Neurotic disorders                            | 6 (1.9)             | 16 (10.3)           | 0.0001  | 12 (5.2)    | 10 (4.2)| 0.67    |
| Depression                                    | 1 (0.3)             | 5 (3.2)             | 0.0167  | 2 (0.9)     | 4 (1.7) | 0.68    |
| ADHD                                          | 31 (9.8)            | 0 (0.0)             | <0.0001 | 17 (7.3)    | 14 (5.9)| 0.58    |
| Development delays                            | 135 (42.9)          | 16 (10.3)           | <0.0001 | 78 (33.6)   | 73 (30.5)| 0.49    |
| Any malignant neoplasms                       | 116 (36.8)          | 51 (32.7)           | 0.4135  | 77 (33.2)   | 90 (37.7)| 0.3359  |
| Oral and pharyngeal cancer                    | 29 (9.2)            | 5 (3.2)             | 0.0218  | 17 (7.3)    | 17 (7.1)| 1.00    |
| Cardiac cancer                                | 4 (1.3)             | 1 (0.6)             | 1.0000  | 2 (0.9)     | 3 (1.3) | 1.00    |
| Urological cancer                             | 4 (1.3)             | 7 (4.5)             | 0.0469  | 6 (2.6)     | 5 (2.1)| 0.77    |
| Brain cancer                                  | 11 (3.5)            | 7 (4.5)             | 0.6146  | 7 (3.0)     | 11 (4.6)| 0.47    |
| Benign tumours                                |                     |                     |         |             |       |         |         |
| Benign skin tumours                           | 6 (1.9)             | 8 (5.1)             | 0.0796  | 6 (2.6)     | 8 (3.3)| 0.79    |
| Benign urological tumours                     | 5 (1.6)             | 17 (10.9)           | <0.0001 | 5 (2.2)     | 17 (7.1)| 0.01    |
| Benign brain tumours                          | 8 (2.5)             | 5 (3.2)             | 0.7667  | 7 (3.0)     | 6 (2.6)| 0.78    |
| Other systemic manifestations                 |                     |                     |         |             |       |         |         |
| Any renal diseases                            | 7 (2.2)             | 23 (14.7)           | <0.0001 | 13 (5.6)    | 17 (7.1)| 0.5734  |
| Myocardial infarction                         | 1 (0.3)             | 0 (0.0)             | 1.0000  | 1 (0.4)     | 0 (0)  | 0.4926  |
| Cerebrovascular diseases                      | 1 (0.3)             | 1 (0.6)             | 0.5532  | 1 (0.4)     | 1 (0.4)| 1.0000  |
| Peptic ulcers                                 | 4 (1.3)             | 6 (3.8)             | 0.0893  | 5 (2.2)     | 5 (2.1)| 1.0000  |
| Diabetes mellitus                             | 1 (0.3)             | 4 (2.6)             | 0.0434  | 2 (0.9)     | 3 (1.3)| 1.0000  |
| LAM                                           | 0 (0.0)             | 3 (2.0)             | 1.0000  | 1 (0.4)     | 2 (0.9)| 1.0000  |

P value was calculated using the T-test, Wilcoxon Rank Sum test, or chi-squared test/Fisher exact test, as appropriate, for comparisons between enrollment age cohorts or sex cohorts. Incidence rate ratio (IRR) was calculated using a generalized linear model to perform Poisson regression analyses. Adjusted IRR was calculated after adjustments were made for comorbidities of epilepsy, dementias, renal diseases, and diabetes, using a generalized linear model. Abbreviations: MR: mortality rate; IRR: incidence rate ratio; SD: standard deviation; IQR: inter-quartile range; TAND: TSC-associated neuropsychiatric disorders; ADHD: attention-deficit hyperactivity disorder; LAM: lymphangioleiomyomatosis.
SMR of 4.8 when compared to age-and-sex-matched controls in the same period. Our results strongly corroborate this number, and show that Asian populations experience a similar SMR for TSC as Caucasian populations, despite potentially lower prevalences and MRs. To the best of our knowledge, this is the first report of TSC SMR in Asian patients. Future research is needed to evaluate the impact of ethnicity on TSC severity.

While Kaplan–Meier function indicates that roughly 4% of TSC patients will die in the first 7 years after enrollment, its mortality plateau suggests that once patients survive the initial years, they might survive for much longer, as survivors usually have milder symptoms. This corroborates the survival data from Chu et al. [11], where most patients survived until adulthood (98.6% survival at 20 years old). The observed trend of decreasing pediatric deaths may be an indication of improved treatment protocols (surgical experience or medication like mTOR inhibitors), criteria, and physician awareness. Notably, those who were enrolled (diagnosed) after age 18 had a significantly worse cumulative mortality curve, with 9.94% mortality by year 7, compared to 1.82% in those enrolled before 18. While it is not possible to directly compare these numbers to the study by Chu et al., we

### Table 3

| Life tables and standardized mortality ratio (SMR) chart for patients with Tuberous Sclerosis Complex (TSC) in Taiwan, 1997–2010. (a) Life table of 100,000 hypothetical TSC patients, based on age at endpoint (death or 2010) and mortality rate (MR). (b) Life table of 100,000 hypothetical TSC patients, based on enrollment age groups and MR. (c) MR and SMR as compared to the general population in the same period |
|---|---|---|---|---|---|---|
| Age at endpoint | TSC patients | Deaths | Probability of death | Expected survivals in hypothetical group | Expected deaths in hypothetical group | Person-years lived between this age group until the next | Total number of person-years lived above age of age group | ARL |
| (a) | | | | | | | | |
| < 1 | 2 | 1 | 0.50 | 100,000 | 50,000 | 2,778 | 97,639 | 3,169,221 | 31.69 |
| 1–18 | 235 | 2 | 0.16 | 50,000 | 7,843 | 18,878 | 1,755,663 | 30,715 | 31.59 |
| 19–40 | 196 | 6 | 0.47 | 42,157 | 19,761 | 645,527 | 815,735 | 19.35 |
| > 40 | 38 | 5 | 1.00 | 22,396 | 22,396 | 170,208 | 170,208 | 7.60 |
| (b) | | | | | | | | |
| < 1 | 36 | 1 | 0.03 | 100,000 | 2,778 | 97,639 | 3,169,221 | 31.69 |
| 1–18 | 279 | 3 | 0.19 | 97,222 | 18,878 | 1,755,663 | 30,715 | 31.59 |
| 19–40 | 129 | 5 | 0.56 | 78,344 | 43,768 | 1,129,206 | 1,315,919 | 16.80 |
| > 40 | 27 | 5 | 1.00 | 34,576 | 34,576 | 186,713 | 186,713 | 5.40 |
| Year | TSC patients | Number of deaths in Taiwan | Population of Taiwan | MR in the general population | Expected deaths (TSC x MR) | Observed deaths in TSC patients |
| 1997 | 8 | 121,000 | 21,742,815 | 0.0056 | 0.04 | 0 |
| 1998 | 20 | 123,180 | 21,928,591 | 0.0056 | 0.11 | 0 |
| 1999 | 21 | 126,113 | 22,092,387 | 0.0057 | 0.12 | 0 |
| 2000 | 19 | 125,958 | 22,276,672 | 0.0057 | 0.11 | 0 |
| 2001 | 21 | 127,647 | 22,405,568 | 0.0057 | 0.13 | 0 |
| 2002 | 36 | 128,636 | 22,520,776 | 0.0057 | 0.21 | 0 |
| 2003 | 57 | 130,801 | 22,604,550 | 0.0058 | 0.33 | 2 |
| 2004 | 22 | 135,092 | 22,689,122 | 0.0060 | 0.14 | 0 |
| 2005 | 65 | 139,398 | 22,770,383 | 0.0061 | 0.40 | 2 |
| 2006 | 50 | 135,839 | 22,876,527 | 0.0059 | 0.30 | 2 |
| 2007 | 44 | 141,111 | 22,958,360 | 0.0061 | 0.27 | 2 |
| 2008 | 43 | 143,624 | 23,037,031 | 0.0062 | 0.27 | 2 |
| 2009 | 39 | 143,582 | 23,119,772 | 0.0062 | 0.24 | 3 |
| 2010 | 23 | 145,772 | 23,162,123 | 0.0063 | 0.14 | 1 |
| Total | 471 | 2,97%/14 years | 2.81/14 years | 0.21%/years | 14/14 years | 0 |

SMR was calculated by the equation because TSC mortality numbers are often at zero for a given year, an average mortality of across 14 years was used instead of year-to-year mortality. ARL, average remaining lifetime; CI, confidence interval.
think it will be interesting to investigate if this pattern of diagnosis-age-dependent mortality persists across these similar populations.

One potential issue affecting SMR in this study is that some patients could have been clinically diagnosed much earlier than their CIC issue date. As a result, our enrollment age (age at CIC acquisition) may be overestimated, and some patients in the late-enrollment cohort may actually belong in the early-enrollment cohort instead, potentially leading to an apparent increase in mortality for late-enrollment patients, or an increase in mean survival time for misclassified individuals. In addition, as CICs were only available for TSC patients from 1997 onward, there is a possibility that TSC patients diagnosed before 1997 may not have been well represented. Fortunately, as our dataset contains only 8 individuals diagnosed in 1997 (Table 3c), and the mortality cohort only contains one individual whose diagnosis date predated 2000 (1999), we believe the skewing of survival time and mortality rate remain minimal.

Our results corroborate the pediatric predominance [14, 43] and frequency (83.5–88.4%) [44] of epilepsy in literature. However, almost all other comorbidities are underrepresented, such as autism spectrum disorder (25–61% literature prevalence) and benign skin neoplasm (22.7–97.2%) [44]. One possible cause is coding limitation: for instance, manifestations like infantile spasms (38–49%) and renal AMLs (> 50%) [45] lack corresponding ICD-9 codes, and cannot be recorded directly. Even assuming recordation under alternate codes (e.g. CNSAs or renal neoplasm), underrepresentation remains likely. Comorbidity ‘masking’ is another possibility: because physicians often note only the chief complaint of a visit, milder symptoms could be ‘masked’ by subjective dismissal in favor of diagnoses regarded as more representative of a visit. Moreover, once TSC is diagnosed, physicians may no longer see the need to record manifestations separately. For TAND, stigmatization of mental illness in East Asian culture [46] may also be a contributing factor.

![Cumulative mortality rate as Kaplan–Meier functions in tuberous sclerosis complex (TSC) patients in Taiwan, 1997–2010.](image-url)
### Table 4
Results of Kaplan–Meier analysis, log-rank test, and Cox regression survival analysis showing bivariate (unadjusted) and multivariate (adjusted) HRs for variables associated with mortality

|                  | Mortality, n (%) | Total patients | Log-rank test | Crude HR (95% CI) | P value | Adjusted HR (95% CI) | P value |
|------------------|------------------|----------------|---------------|-------------------|---------|----------------------|---------|
| **Enrollment age** |                  |                |               |                   |         |                      |         |
| ≤ 18             | 4 (1.26)         | 315            | 1.00          |                   | 1.00    |                      | 1.00    |
| > 18             | 10 (6.42)        | 156            | 0.0003        | 6.54 (2.03–21.04) | 0.0016  | 5.97 (1.74–20.47)    | 0.0045  |
| **Sex**          |                  |                |               |                   |         |                      |         |
| Males            | 8 (3.44)         | 232            | 1.00          |                   | 1.00    |                      | 1.00    |
| Females          | 6 (2.52)         | 239            | 0.6011        | 0.75 (0.26–2.18)  | 0.6023  | 0.69 (0.24–2.02)     | 0.4971  |
| **Comorbidity**  |                  |                |               |                   |         |                      |         |
| **Neurological symptoms** |          |                |               |                   |         |                      |         |
| Epilepsy         |                  |                |               |                   |         |                      |         |
| No               | 4 (3.64)         | 110            | 1.00          |                   | 1.00    |                      | 1.00    |
| Yes              | 10 (2.78)        | 361            | 0.3575        | 0.58 (0.18–1.87)  | 0.3633  | 0.84 (0.25–2.82)     | 0.7829  |
| Cerebral degenerations |       |                |               |                   |         |                      |         |
| No               | 14 (3.0)         | 463            | 1.00          |                   | 1.00    |                      | 1.00    |
| Yes              | 0 (0.0)          | 8              | 0.6026        |                   |         |                      |         |
| Multiple sclerosis |               |                |               |                   |         |                      |         |
| No               | 13 (2.9)         | 447            | 1.00          |                   | 1.00    |                      | 1.00    |
| Yes              | 1 (4.2)          | 24             | 0.9193        | 1.11 (0.14–8.52)  | 0.9193  | 1.24 (0.12–12.52)    | 0.8554  |
| Infantile cerebral palsy |         |                |               |                   |         |                      |         |
| No               | 12 (2.8)         | 424            | 1.00          |                   | 1.00    |                      | 1.00    |
| Yes              | 2 (4.3)          | 47             | 0.7852        | 1.23 (0.27–5.52)  | 0.7855  | 6.03 (0.97–37.46)    | 0.0540  |
| Other congenital nervous system anomalies | |                |               |                   |         |                      |         |
| No               | 11 (3.3)         | 329            | 1.00          |                   | 1.00    |                      | 1.00    |
| Yes              | 3 (2.1)          | 142            | 0.2588        | 0.49 (0.13–1.75)  | 0.2689  | 0.78 (0.17–3.69)     | 0.7567  |
| **TANDs**        |                  |                |               |                   |         |                      |         |
| Dementias        |                  |                |               |                   |         |                      |         |
| No               | 13 (2.96)        | 440            | 1.00          |                   | 1.00    |                      | 1.00    |
| Yes              | 1 (3.22)         | 31             | 0.9931        | 1.01 (0.13–7.72)  | 0.993   | 0.5 (0.06–3.97)      | 0.5119  |
| Psychotic conditions |              |                |               |                   |         |                      |         |
| No               | 13 (3.3)         | 398            | 1.00          |                   | 1.00    |                      | 1.00    |
| Yes              | 1 (1.4)          | 73             | 0.3052        | 0.36 (0.05–2.76)  | 0.3261  | –                     | –       |
| Neurotic disorders |              |                |               |                   |         |                      |         |
| No               | 14 (3.1)         | 449            | 1.00          |                   | 1.00    |                      | 1.00    |
| Yes              | 0 (0.0)          | 22             | 0.3789        |                   |         |                      |         |
| Depression       |                  |                |               |                   |         |                      |         |
| No               | 14 (3.0)         | 465            | 1.00          |                   | 1.00    |                      | 1.00    |
| Yes              | 0 (0.0)          | 6              | 0.6456        |                   |         |                      |         |
| ADHD             |                  |                |               |                   |         |                      |         |
| No               | 14 (3.2)         | 440            | 1.00          |                   | 1.00    |                      | 1.00    |
| Yes              | 0 (0.0)          | 31             | 0.2862        |                   |         |                      |         |
| Developmental delays |              |                |               |                   |         |                      |         |
| No               | 13 (4.1)         | 320            | 1.00          |                   | 1.00    |                      | 1.00    |
| Yes              | 1 (0.7)          | 151            | 0.0270        | 0.14 (0.02–1.07)  | 0.0583  | 0.24 (0.02–2.34)     | 0.2195  |
| Any malignant neoplasms |         |                |               |                   |         |                      |         |
| No               | 9 (2.96)         | 304            | 1.00          |                   | 1.00    |                      | 1.00    |
| Yes              | 5 (3.00)         | 167            | 0.5822        | 0.73 (0.24–2.22)  | 0.5836  | 0.62 (0.19–2.07)     | 0.4413  |
| Oral & pharyngeal cancer |        |                |               |                   |         |                      |         |
| No               | 13 (3.0)         | 437            | 1.00          |                   | 1.00    |                      | 1.00    |
| Yes              | 1 (2.9)          | 34             | 0.7634        | 0.73 (0.1–5.63)   | 0.7647  | 1.14 (0.1–12.48)     | 0.9161  |
Table 4 (continued)

| Mortality, n (%) | Total patients | Log-rank test | Crude HR (95% CI) | P value | Adjusted HR (95% CI) | P value |
|-----------------|----------------|---------------|-------------------|---------|----------------------|---------|
| Cardiac cancer  |                |               |                   |         |                      |         |
| No              | 14 (3.0)       | 466           | 1.00              | 1.00    |                      |         |
| Yes             | 0 (0.0)        | 5             | 0.7087            | –       | –                    | –       |
| Urological cancer|               |               |                   |         |                      |         |
| No              | 13 (2.8)       | 460           | 1.00              | 1.00    |                      |         |
| Yes             | 1 (9.1)        | 11            | 0.2763            | 2.94 (0.38–22.49) | 0.2993       | 1.87 (0.17–21.26) | 0.6121 |
| Brain cancer    |                |               |                   |         |                      |         |
| No              | 14 (3.1)       | 453           | 1.00              | 1.00    |                      |         |
| Yes             | 0 (0.0)        | 18            | 0.4122            | –       | –                    | –       |
| Benign tumours  |                |               |                   |         |                      |         |
| Benign skin tumour|              |               |                   |         |                      |         |
| No              | 14 (3.1)       | 457           | 1.00              | 1.00    |                      |         |
| Yes             | 0 (0.0)        | 14            | 0.4934            | –       | –                    | –       |
| Benign urological tumour | |               |                   |         |                      |         |
| No              | 11 (2.4)       | 449           | 1.00              | 1.00    |                      |         |
| Yes             | 3 (13.6)       | 22            | 0.0016            | 6.11 (1.70–22.03) | 0.0057       | 3.34 (0.72–15.64) | 0.1250 |
| Benign brain tumour |             |               |                   |         |                      |         |
| No              | 13 (2.8)       | 458           | 1.00              | 1.00    |                      |         |
| Yes             | 1 (7.7)        | 13            | 0.3333            | 2.63 (0.34–20.1) | 0.3519       | 5.85 (0.52–66.02) | 0.1533 |
| Other systemic manifestations | |               |                   |         |                      |         |
| Any renal diseases |              |               |                   |         |                      |         |
| No              | 11 (2.50)      | 441           | 1.00              | 1.00    |                      |         |
| Yes             | 3 (10.00)      | 30            | 0.0149            | 4.29 (1.19–15.41) | 0.0256       | 2.25 (0.53–9.51) | 0.2688 |
| Myocardial infarctions | |               |                   |         |                      |         |
| No              | 14 (2.98)      | 470           | 1.00              | 1.00    |                      |         |
| Yes             | 0 (0.00)       | 1             | 0.8690            | –       | –                    | –       |
| Cerebrovascular diseases | |               |                   |         |                      |         |
| No              | 14 (2.98)      | 469           | 1.00              | 1.00    |                      |         |
| Yes             | 0 (0.00)       | 2             | 0.8429            | –       | –                    | –       |
| Peptic ulcers   |                |               |                   |         |                      |         |
| No              | 13 (2.82)      | 461           | 1.00              | 1.00    |                      |         |
| Yes             | 1 (10.00)      | 10            | 0.3113            | 2.74 (0.36–21.08) | 0.3316       | 1.75 (0.18–17.48) | 0.6327 |
| Diabetes mellitus |              |               |                   |         |                      |         |
| No              | 14 (3.00)      | 466           | 1.00              | 1.00    |                      |         |
| Yes             | 0 (0.00)       | 5             | 0.6947            | –       | –                    | –       |
| LAM             |                |               |                   |         |                      |         |
| No              | 14 (3.00)      | 468           | 1.00              | 1.00    |                      |         |
| Yes             | 0 (0.00)       | 3             | –                 | –       | –                    | –       |

Kaplan–Meier estimates of survival and log rank test were used to initially identify those variables associated with mortality. Crude hazard ratio (HR) and their P values were calculated by using the Cox proportional hazards regression model. Adjusted hazard ratio (HR) and their P values were calculated by using the stepwise Cox proportional hazards regression model. TAND, TSC-associated neuropsychiatric disorders; ADHD, attention-deficit hyperactivity disorder; LAM, lymphangioleiomyomatosis

Notably, LAM was only found in 3 TSC patients (2 female, 1 male; 0.7%), compared to a literature prevalence of around 28% [47]. The presence of a male case is also noteworthy, as LAM is traditionally accepted as a predominantly female manifestation. However, lung computed tomography scans have revealed a 13% prevalence of LAM-like lesions in male TSC patients [47], indicating that LAM is perhaps not as rare in males as previously thought. A single-center study of 10 LAM patients in Taiwan during a similar period (1990–2001) found none to be diagnosed with TSC [48], although it is possible that these represent undiagnosed TSC cases or chimeric expressions of somatic TSC gene mutations [49].
TSC mortality causes are complex, and further complicated by the scarcity of literature and the partial attributability of some deaths. One American study (n = 355, nmortality = 40) [38] found renal diseases (27.5%), brain tumours (25%), and pulmonary LAM (10%) to be major causes, with 32.5% deaths associated with severe intellectual disability. Other reports have found renal diseases [6, 40] and epilepsy-related manifestations [29] to be major causes. Overall, the most common TSC-attributable causes seem to be renal manifestations, epilepsy, secondary infections, and pulmonary LAM. Consistently, we found renal diseases and benign urological tumours to be associated with mortality. On the other hand, none of the 3 LAM patients in our study died during the query period, which may be a result of the relatively shorter follow-up time, since LAM progresses gradually and significant morbidity usually only occur during the later stages of disease. The high renal AML prevalence in older TSC patients [50–52], and its significance as a cause of death, could potentially explain our reported association between late enrollment and mortality.

Our study contains some potential limitations. Firstly, as previously mentioned, mortality causes were unavaila-
ble, limiting conclusions to association and not causation. Other data made unavailable through NHIRD restrictions include patient genotype and symptom severity (e.g. degree of intellectual disability), which may have helped elucidate or corroborate past literature; and prescriptions or examinations ordered in the outpatient setting (e.g. medication or radiographic scans), which may have helped to determine the effect of anticonvulsants or mTOR inhibitors on moderating mortality. mTOR inhibitors, especially, have become increasingly common in recent years, with a recent study reporting 37% use in TSC patients in 2019 [53]. The absence of these data creates obvious gaps in our observations, and results should be taken with these shortcomings in mind. Secondly, changes in diagnostic criteria, as well as insufficient diagnostic awareness, may have excluded subjects especially in the earlier years of CIC implementation, and national prevalence may have been underestimated.

Conclusions

We report a national, population-based dataset of 471 TSC patients across a period of 14 years, the largest population-based study of Asian TSC patients to date. When compared to past (predominantly Caucasian-based) literature, results indicate similar demographics, partially similar manifestations and frequencies, lower prevalence, lower MR, and near-identical SMR. Enrollment (diagnosis) age was found to be a significant prognostic factor, with late-enrollment patients at higher risk for all-cause mortality and lower ARL. A relatively low cumulative mortality was found, which plateaued at 7 years post-enrollment, suggesting a good survival rate after patients survive the initial stages of the disease, which corroborates previous data from other studies in Asian TSC patients. Overall, multidisciplinary awareness and evaluation is vital for the early diagnosis and adequate management of TSC, which in turn improves disease outcome and patient survival.

Abbreviations

ADHD: Attention-deficit hyperactivity disorder; AML: Angiomylipoma; ARL: Average remaining lifetime; CIC: Catastrophic Illness Certificate; CNSA: Congenital nervous system anomalies; DM: Diabetes mellitus; HR: Hazard ratio; ICD-9-CM: International Classification of Diseases, 9th Revision, Clinical Modification; ICP: Infantile cerebral palsy; IRR: Incidence rate ratio; LAM: Lymphangioleiomyomatosis; MR: Mortality rate; mTOR: Mammalian target of rapamycin; NIH: National Health Insurance; NHIRD: National Health Insurance Research Database; PY: Person-years; SMR: Standardized mortality ratio; TAND: Tuberous sclerosis complex-associated neuropsychiatric disorders; TOSCA: Tuberous sclerosis registry to increase disease awareness; TSC: Tuberous sclerosis complex.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13023-021-01974-3.

Additional file 1: Fig. S1. Enrollment age distribution by sex for survival group Tuberous Sclerosis Complex (TSC) patients in Taiwan, 1997–2010. Enrollment age was defined as the age of acquisition of catastrophic illness certificate for TSC. Total patient number was 457. Both male and female patients were most frequently enrolled at ages 1–5. Additional file 2: Table S1. Comparisons between the mortality and survival cohorts in male and female tuberous sclerosis complex (TSC) patients. Additional file 3: Table S2. Profile of tuberous sclerosis complex (TSC) patients who died during 1997–2010. Additional file 4: Table S3. Subgroup analyses for mortality in associated variables in late and early onset tuberous sclerosis complex (TSC) patient cohorts. Additional file 5. Fig. S2. Map of regional or national prevalence of Tuberous Sclerosis Complex in available literature. Data may represent only regional values in a nation. Data may be estimates according to clinical- or population-based methodology. Region and source of data include: Taiwan (National, population-based using health insurance database, 1/63, 290); Hong Kong (Regional, clinical-based, 1/170, 000 [30]; regional, population-based using hospital administration database, 1/25, 833 [11]); Japan (Regional in San-in, clinical-based, 1/31, 000 [22]); United Kingdom (Regional in western Scotland, 1/27, 000 [23]; southern England, 1/26, 500 [24]; the Oxford region, 1/29, 990 [25]; and Northern Ireland, 1/25, 000 [26]; all clinical-based), Sweden (Regional in western Sweden, clinical-based, 1/12, 900 [27]; national, population-based using health insurance registry, 1/18, 587 [33]); the United States (Regional in Olmsted county, Minnesota, 1/14, 490 [28]; and Rochester, Minnesota, 1/9, 434 [29]; both clinical-based), Canada (Provincial in Quebec, population-based using health-care database, 1/7, 872 [34]); and Germany (National, population-based using surveys sent to pediatric clinics and TSC centers, 1/11, 180 to 22, 360 live births [31, 32]).

Acknowledgements

The authors would like to thank Dr. Chi‑Hong Lee for his help and expertise in the advisement and preparation of this manuscript.
2. Henske EP, Jóźwiak S, Kingswood JC, Sampson JR, Thiele EA. Tuberous

Health and managed by National Health Research Institutes, and are available

provided by the Taiwan Bureau of National Health Insurance, Department of

Availability of data and materials

Kaohsiung Veterans General Hospital, Taiwan.

Ministry of Science and Technology, Taiwan, as well as VGHKS109-120 from the

Department of Public Health and Environmental Medicine, School of Medi‑

1 Department of Dermatology, School of Medicine, National Yang Ming Chiao

Authors' contributions

All authors were involved in the conception and design of the study. JHP

aided in the analysis and interpretation of the patient dataset, and drafted

and substantially revised the manuscript. HPT was a major contributor to the

analysis and interpretation of the patient database, including its statistical

methods and the construction of tables and figures. CHH aided in the analysis

and interpretation of the dataset, and was also responsible for the acquisition

of the dataset, and the acquisition of relevant funding. All authors have read

and approved of the final manuscript.

Funding

This work was supported in part by MOST-108-2314-B-010-045-MY3 from the

Ministry of Science and Technology, Taiwan, as well as VHKS109-120 from the

Kaohsiung Veterans General Hospital, Taiwan.

Availability of data and materials

Data was obtained from the National Health Insurance Research Database

provided by the Taiwan Bureau of National Health Insurance, Department of

Health and managed by National Health Research Institutes, and are available

from the authors with the permission of the Taiwan Bureau of National Health

Insurance.

Declarations

Ethics approval and consent to participate

Ethical review and approval were waived for this study (study 0103-34948), by

the Chang Gung Memorial Foundation Institutional Review Board, due to suf‑

ficient scrambling of personal and potentially identifying patient

information at the time of data query. Patient consent was likewise waived

due to sufficient scrambling of personal and potentially identifying patient

information at the time of data query.

Consent for publication

Not applicable.

Competing interests

The authors declare no conflict of interest. The funders had no role in the

design of the study; in the collection, analyses, or interpretation of data, in the

writing of the manuscript, or in the decision to publish the results.

Author details

1 Department of Dermatology, School of Medicine, National Yang Ming Chiao

Tung University, Taipei City 112, Taiwan. 2 Department of Medical Education,

Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City 833, Taiwan.

3 Department of Public Health and Environmental Medicine, School of Medi‑

ne, College of Medicine, Kaohsiung Medical University, Kaohsiung City 807,

Taiwan. 4 Department of Dermatology, Kaohsiung Veterans General Hospital,

Kaohsiung City 813, Taiwan.

Received: 10 February 2021 Accepted: 19 July 2021

Published online: 03 August 2021

References

1. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med. 2006;355(13):1345–56. https://doi.org/10.1056/NEJMra

a055323.

2. Henske EP, Jóźwiak S, Kingswood JC, Sampson JR, Thiele EA. Tuberous

sclerosis complex. Nat Rev Dis Primers. 2016;2:16035. https://doi.org/10.1038/rdp.2016.35.

3. Curatolo P, Moavero R, de Vries PJ. Neurological and neuropsychiatric

aspects of tuberous sclerosis complex. Lancet Neurol. 2015;14(7):733–

45. https://doi.org/10.1016/S1474-4422(15)00069-1.

4. Lee CH. Topical rapamycin combined with calcitriol in treating angiofi‑

bromas in tuberous sclerosis complex. Br J Dermatol. 2020;183(4):604–

6. https://doi.org/10.1111/bjd.19060.

5. Tye C, McEwen FS, Liang H, et al. Long-term cognitive outcomes in tuber‑

ous sclerosis complex. Dev Med Child Neurol. 2020;62(3):322–9. https://
doi.org/10.1111/dmcn.14356.

6. Amin S, Lux A, Calder N, Laughhorne M, Osborne J, O’callaghan F. Causes of mortality in individuals with tuberous sclerosis complex. Dev Med Child Neurol. 2017;59(6):612–7. https://doi.org/10.1111/dmcn.13352.

7. Kobayashi T, Unakami S, Hirayama Y, et al. Intragenic Tsc2 somatic muta‑
tions as Knudson’s second hit in spontaneous and chemically induced

renal carcinomas in the Eker rat model. Jpn J Cancer Res. 1997;88(3):254–

61. https://doi.org/10.1111/1349-7006.1997.tb03375.x.

8. Bournelie DM. Sclère tubéreuse : considérations cliniques et neuroradi‑

ologiques. Acta Neurochir (Wien). 1880;1:81–91.

9. Hong CH, Darling TN, Lee CH. Prevalence of tuberous sclerosis complex in

Taiwan: a national population-based study. Neuroepidemiology. 2009;33(4):335–41. https://doi.org/10.1159/000254569.

10. Hong CH, Tu HP, Lin JR, Lee CH. An estimation of the incidence of

tuberous sclerosis complex in a nationwide retrospective cohort study

(1997–2010). Br J Dermatol. 2016;174(6):1282–9. https://doi.org/10.1111/ bd.14415.

11. Chu WC, Chiang LL, Chan DC, Wong WH, Chan GC. Prevalence, mortality

and healthcare economic burden of tuberous sclerosis in Hong Kong: a

population-based retrospective cohort study (1995–2018). Orphanet J Rare

Dis. 2020;15(1):264. https://doi.org/10.1186/s13023-020-01517-2.

12. Amin S, Lux A, Calder N, Laughhorne M, Osborne J, O’callaghan F. Causes of mortality in individuals with tuberous sclerosis complex. Dev Med Child Neurol. 2017;59(6):612–7. https://doi.org/10.1111/dmcn.13352.

13. Seibert D, Hong CH, Takeuchi F, et al. Recognition of tuberous sclerosis in

adult women: delayed presentation with life-threatening consequences. Ann Intern Med. 2011;154(12):806–294. https://doi.org/10.7326/0003-

4819-154-12-201106210-00008.

14. Staley BA, Vail EA, Thiele EA. Tuberous sclerosis complex: diagnostic chal‑

lenges, presenting symptoms, and commonly missed signs. Pediatrics. 2011;127(1):e117–25. https://doi.org/10.1542/peds.2010-0192.

15. National residents enrolled in the National Health Insurance: NHRI Open

Data. https://data.nhri.gov.tw/Datasets/DatasetDetail.aspx?id=41&MidId= A150258. Published 2016 May. Last updated 2019 Apr. Accessed 2019

Oct.

16. Population statistics. Dept. of Household Registration, Ministry of Interior.

www.ris.gov.tw/app/portal/346. Published 1998 Jan. Last updated 2020

Jan. Accessed 2020 Jan.

17. Roach ES, Smith M, Huttonlocher P, Bhat M, Alcorn D, Hawley L. Diagnos‑
tic criteria: tuberous sclerosis complex. Report of the Diagnostic Criteria

Committee of the National Tuberous Sclerosis Association. J Child Neurol.

1992;7(2):221–4. https://doi.org/10.1177/088307389200700219.

18. Roach ES, Gomez MR, Northrup H. Tuberous sclerosis complex cons‑
sensus conference: revised clinical diagnostic criteria. J Child Neurol.

1998;13(2):624–8. https://doi.org/10.1177/08830738981301206.

19. Yang Z, Sun X. SAS® Macros for Generating Abridged and Cause‑

Eliminated Life Tables. SAS Users Group International (SUGI) Proceedings.

2006; paper 047–31.

20. Vincent A, Zheng S. Life Expectancy Tables: Getting SAS

Math. SAS Global Forum Proceedings. 2019; paper 3064‑2019

21. Gordis L. Epidemiology, Fifth Edition. Philadelphia, PA: Elsevier Saunders;

2014.

22. Ohno K, Takeshita K, Arima Y, Morisaki K. Frequency of tuberous sclerosis in San‑in district (Japan) and birth weight of patients with tuberous sclerosis. Brain Dev. 1981;3(1):57–64. https://doi.org/10.1016/0367‑7604(81)80007-1.

23. Sampson JR, Scahiil SJ, Stephenson JB, Mann L, Connor JM. Genetic

aspects of tuberous sclerosis in the west of Scotland. J Med Genet. 1989;26(1):28–31. https://doi.org/10.1136/jmg.26.1.28.

24. Webb DW, Fryer AE, Osborne JP. Morbidity associated with tuberous

sclerosis: a population study. Dev Med Child Neurol. 1996;38(2):146–55. https://doi.org/10.1111/j.1469‑8749.1996.tb12086.x.

25. Hunt A, Lindenbaum RH: Tuberous sclerosis: a new estimate of preva‑
lence within the Oxford region. J Med Genet. 1984;21(4):272–7. https://
doi.org/10.1136/jmg.21.4.272.

26. Devlin LA, Shepherd CR, Crawford H, Morrison PJ. Tuberous sclerosis

complex: clinical features, diagnosis, and prevalence within Northern

Ireland. Dev Med Child Neurol. 2006;48(6):495–9. https://doi.org/10.1017/ S0012162606001058.
27. Ahlsén G, Gillberg IC, Lindblom R, Gillberg C. Tuberous sclerosis in Western Sweden: a population study of cases with early childhood onset. Arch Neurol. 1994;51(1):76–81. https://doi.org/10.1001/archneur.1994.00540130110018.

28. Shepherd CW, Beard CM, Gomez MR, Kurland LT, Whisnant JP. Tuberous sclerosis complex in Olmsted County, Minnesota, 1950–1989. Arch Neurol. 1991;48(4):400–1. https://doi.org/10.1001/archneur.1991.005301600815.

29. Wiederhold WC, Gomez MR, Kurland LT. Incidence and prevalence of tuberous sclerosis in Rochester, Minnesota, 1950 through 1982. Neurol. 1985;35(4):600–3. https://doi.org/10.1212/wnl.35.4.600.

30. Singer K. Genetic aspects of tuberous sclerosis in a Chinese population. Am J Hum Genet. 1971;23(1):33–40.

31. Ebrahimi-Fakhari D, Mann LL, Poryo M, et al. Incidence of tuberous sclerosis and age at first diagnosis: new data and emerging trends from a national, prospective surveillance study [published correction appears in Orphanet J Rare Dis. 2019 May 13;14(1):106]. Orphanet J Rare Dis. 2018;19(1):117. https://doi.org/10.1186/s13023-018-0870-y.

32. Ebrahimi-Fakhari D, Mann LL, Poryo M, et al. Correction to: Incidence of tuberous sclerosis and age at first diagnosis: new data and emerging trends from a national, prospective surveillance study. Orphanet J Rare Dis. 2019;14(1):106. https://doi.org/10.1186/s13023-019-1090-9.

33. Welin KO, Carlqvist P, Svensson A, Althin R, Eklund E, Rask O. Epilepsy in tuberous sclerosis patients. Epilepsia. 1986;27(4):354–62. https://doi.org/10.1111/j.1468-1327.1986.tb03681.x.

34. Kristof AS, Zhi Li P, Major P, Landry JS. Lymphangioleiomyomatosis and tuberous sclerosis in Olmsted County, Minnesota, 1950–1989. Arch Neurol. 1991;48(4):400–1. https://doi.org/10.1001/archneur.1991.005301600815.

35. Morrison PJ. Tuberous sclerosis: epidemiology, genetics and progress. Chest. 2015;148(2):444–9. https://doi.org/10.1378/chest.14-3095.

36. Kristof AS, Zhi Li P, Major P, Landry JS. Lymphangioleiomyomatosis and tuberous sclerosis complex in Quebec: prevalence and health-care utilization, treatment, morbidity, and mortality using national register data. Seizure. 2017;53:4–9. https://doi.org/10.1016/j.seizure.2017.10.005.

37. Kingswood JC, d’Augères GB, Belousova E, et al. TuberOus SClerosis registry to increase disease Awareness (TOSCA)—baseline data on 2093 patients. Orphanet J Rare Dis. 2017;12(1):12. https://doi.org/10.1186/s13023-016-0553-5.

38. Shepherd CW, Gomez MR, Lie JT, Crowson CS. Causes of death in patients with tuberous sclerosis. Mayo Clin Proc. 1991;66(8):792–6. https://doi.org/10.1016/0025-6196(91)90054-K.

39. Kingswood JC, Belousova E, Benedik MP, et al. Pulmonary lymphangioleiomyomatosis in female and male patients with tuberous sclerosis complex. Clin Radiol. 2011;66(7):623–6. https://doi.org/10.1016/j.crad.2011.02.009.

40. Adriaensen ME, Schaefier-Prokop CM, Duymdam DA, Zonnenberg BA, Prokop M. Radiological evidence of lymphangioleiomyomatosis in a man as a result of extreme mosaicism for a TSC2 mutation. Ann Am Thorac Soc. 2017;14(7):1277–9. https://doi.org/10.1513/AnnalsATS.201703-229LE.

41. Eijkemans MJ, van der Wal W, Reijnders LJ, et al. Long-term follow-up assessing renal angiomyolipoma treatment patterns, morbidity, and mortality: an observational study in tuberous sclerosis complex patients in the Netherlands. Am J Kidney Dis. 2015;66(4):638–45. https://doi.org/10.1053/j.ajkd.2015.05.016.

42. Shepherd CW, Gomez MR. Mortality in the Mayo Clinic tuberous sclerosis complex study. Ann N Y Acad Sci. 1991;615:375–7. https://doi.org/10.1111/j.1749-6632.1991.tb37786.x.

43. Zie J, Mokhallati N, Su W, et al. Lymphangioleiomyomatosis mortality in patients with tuberous sclerosis complex. Ann Am Thorac Soc. 2019;16(4):509–12. https://doi.org/10.1513/AnnalsATS.201807-471RL.

44. Nabbout R, Belousova E, Benedik MP, et al. Epilepsy in tuberous sclerosis complex: findings from the TOSCA Study. Epilepsia Open. 2018;3(1):73–84. https://doi.org/10.1002/epio.12286.

45. Zöllner JP, Franz DN, Herzberg C, et al. A systematic review on the burden of illness in individuals with tuberous sclerosis complex (TSC). Orphanet J Rare Dis. 2020;15(1):23. https://doi.org/10.1186/s13023-019-1258-3.

46. Lu DS, Karas PJ, Krueger DA, Weiner HL. Central nervous system manifestations of tuberous sclerosis complex. Am J Med Genet C Semin Med Genet. 2018;178(3):291–8. https://doi.org/10.1002/ajmgc.31647.

47. Adriaensen ME, Schaefier-Prokop CM, Duymdam DA, Zonnenberg BA, Prokop M. Pulmonary lymphangioleiomyomatosis—a clinicopathological analysis of ten cases. Chang Gung Med J. 2004;27(3):201–9.

48. Han MK, Tyburczy ME, Darling TN, et al. Apparent sporadic lymphangioleiomyomatosis in a man as a result of extreme mosaicism for a TSC2 mutation. Ann Am Thorac Soc. 2017;14(7):1277–9. https://doi.org/10.1513/AnnalsATS.201703-229LE.

49. Webb DW, Kabala J, Osborne JP. A population study of renal disease in patients with tuberous sclerosis. Br J Urol. 1994;74(2):151–4. https://doi.org/10.1053/j.ajkd.2015.05.016.

50. Webb DW, Kabala J, Osborne JP. A population study of renal disease in patients with tuberous sclerosis. Br J Urol. 1994;74(2):151–4. https://doi.org/10.1053/j.ajkd.2015.05.016.

51. Nielson CP, Sando MG. Contemporary diagnosis and management of renal angiomylipoma. J Urol. 2002;168(4 Pt 1):1315–25. https://doi.org/10.1097/01.ju.0000028200.86216.b2.

52. Kingswood JC, Belousova E, Benedik MP, et al. Renal angiomylipoma in patients with tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increase disease Awareness. Nephrol Dial Transplant. 2019;34(3):502–8. https://doi.org/10.1093/ndt/gfy063.

53. Zöllner JP, Grau J, Rosenov F, et al. Direct and indirect costs and cost-driving factors in adults with tuberous sclerosis complex: a multicenter cohort study and a review of the literature. Orphanet J Rare Dis. 2021;16(1):250. https://doi.org/10.1186/s13023-021-01838-w.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions